Inhibitory role of the small leucine-rich proteoglycan biglycan in bladder cancer

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Niedworok, Christian ^a   Roc̈k, Katharina ^b   Kretschmer, Inga ^b   Freudenberger, Till ^b   Nagy, Nadine ^b   Szarvas, Tibor ^c   Vom Dorp, Frank ^a   Reis, Henning ^a   Rub̈ben, Herbert ^a   Fischer, Jens W ^b  

^a UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BIGLYCAN; MESSENGER RNA; SHORT HAIRPIN RNA; SORAFENIB; SUNITINIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; CANCER SURVIVAL; CARBOHYDRATE ANALYSIS; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG POTENTIATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KAPLAN MEIER METHOD; MALE; MOUSE; MOUSE MODEL; NONHUMAN; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR BIOPSY; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; BIGLYCAN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; LEUCINE; MALE; MICE; MICE, NUDE; NIACINAMIDE; PHENYLUREA COMPOUNDS; PYRROLES; RNA, MESSENGER; URINARY BLADDER NEOPLASMS;

EID: 84892401456     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080084     Document Type: Article

References (53)

1. Ploeg M, Aben KK, Kiemeney LA (2009) The present and future burden of urinary bladder cancer in the world. World J Urol 27: 289-293. doi: 10.1007/s00345-009-0383-3. PubMed: 19219610.
2. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A et al. (2011) EAU guidelines on non-muscle-invasive urothelial carcinoms of the bladder, the 2011 update. Eur Urol 59: 997-1008. doi:10.1016/j.eururo.2011.03. 017. PubMed: 21458150.
3. Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS et al. (2011) Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 59: 1009-1018. doi:10.1016/j.eururo.2011.03.023. PubMed: 21454009.
4. Agarwal N, Hussain M (2009) Management of bladder cancer: current and emerging strategies. Drugs 69: 1173-1187. doi: 10.2165/00003495-200969090-00003. PubMed: 19537835.
5. Zhu Z, Shen Z, Xu C (2012) Targeted therapy for advanced urothelial cancer of the bladder: where do we stand? Anti Cancer Agents Med Chem 12: 1081-1087. doi:10.2174/187152012803529673. PubMed: 22583418.
6. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ et al. (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349: 859-866. doi:10.1056/NEJMoa022148. PubMed: 12944571.
7. Kaufman DS, Shipley WU, Feldman AS (2009) Bladder cancer. Lancet 374: 239-249. doi:10.1016/S0140-6736(09)60491-8. PubMed: 19520422.
8. Iozzo RV, Sanderson RD (2011) Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med 15: 1013-1031. doi:10.1111/j.1582-4934.2010.01236.x. PubMed: 21155971.
9. Hildebrand A, Romarís M, Rasmussen LM, Heinegård D, Twardzik DR et al. (1994) Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J 302 (2): 527-534. PubMed: 8093006.
10. Inkson CA, Ono M, Bi Y, Kuznetsov SA, Fisher LW et al. (2009) The potential functional interaction of biglycan and WISP-1 in controlling differentiation and proliferation of osteogenic cells. Cells Tissues Organs 189: 153-157. doi:10.1159/000151377. PubMed: 18701807.
11. Tufvesson E, Westergren-Thorsson G (2002) Tumour necrosis factor-alpha interacts with biglycan and decorin. FEBS Lett 530: 124-128. doi: 10.1016/S0014-5793(02)03439-7. PubMed: 12387878.
12. Iozzo RV, Schaefer L (2010) Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucinerich proteoglycans. FEBS J 277: 3864-3875. doi:10.1111/j. 1742-4658.2010.07797.x. PubMed: 20840584.
13. Babelova A, Moreth K, Tsalastra-Greul W, Zeng-Brouwers J, Eickelberg O et al. (2009) Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J Biol Chem 284: 24035-24048. doi:10.1074/jbc.M109. 014266. PubMed: 19605353.
14. Schaefer L, Babelova A, Kiss E, Hausser HJ, Baliova M et al. (2005) The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 115: 2223-2233. doi:10.1172/JCI23755. PubMed: 16025156.
15. Kinsella MG, Fischer JW, Mason DP, Wight TN (2000) Retrovirally mediated expression of decorin by macrovascular endothelial cells. Effects on cellular migration and fibronectin fibrillogenesis in vitro. J Biol Chem 275: 13924-13932. doi:10.1074/jbc.275.18.13924. PubMed: 10788518.
16. Melchior-Becker A, Dai G, Ding Z, Schäfer L, Schrader J et al. (2011) Deficiency of biglycan causes cardiac fibroblasts to differentiate into a myofibroblast phenotype. J Biol Chem 286: 17365-17375. doi:10.1074/jbc.M110. 192682. PubMed: 21454527.
17. Yamamoto K, Ohga N, Hida Y, Maishi N, Kawamoto T et al. (2012) Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells. Br J Cancer 106: 1214-1223. doi:10.1038/bjc.2012.59. PubMed: 22374465.
18. Zhang G, Chen S, Goldoni S, Calder BW, Simpson HC et al. (2009) Genetic evidence for the coordinated regulation of collagen fibrillogenesis in the cornea by decorin and biglycan. J Biol Chem 284: 8888-8897. PubMed: 19136671.
19. Aprile G, Avellini C, Reni M, Mazzer M, Foltran L et al. (2013) Biglycan expression and clinical outcome in patients with pancreatic adenocarcinoma. Tumour Biol 34: 131-137. doi:10.1007/s13277-012-0520-2. PubMed: 23007878.
20. Gu X, Ma Y, Xiao J, Zheng H, Song C et al. (2012) Up-regulated biglycan expression correlates with the malignancy in human colorectal cancers. Clin Exp Med 12: 195-199. doi:10.1007/s10238-011-0155-4. PubMed: 21879307.
21. Wang B, Li GX, Zhang SG, Wang Q, Wen YG et al. (2011) Biglycan expression correlates with aggressiveness and poor prognosis of gastric cancer. Exp Biol Med (Maywood) 236: 1247-1253. doi:10.1258/ebm.2011.011124. PubMed: 21998129.
22. Weber CK, Sommer G, Michl P, Fensterer H, Weimer M et al. (2001) Biglycan is overexpressed in pancreatic cancer and induces G1-arrest in pancreatic cancer cell lines. Gastroenterology 121: 657-667. doi:10.1053/gast.2001.27222. PubMed: 11522750.
23. Recktenwald CV, Leisz S, Steven A, Mimura K, Müller A et al. (2012) HER-2/neu-mediated down-regulation of biglycan associated with altered growth properties. J Biol Chem 287: 24320-24329. doi:10.1074/jbc.M111.334425. PubMed: 22582394.
24. Hwang JY, Johnson PY, Braun KR, Hinek A, Fischer JW et al. (2008) Retrovirally mediated overexpression of glycosaminoglycan-deficient biglycan in arterial smooth muscle cells induces tropoelastin synthesis and elastic fiber formation in vitro and in neointimae after vascular injury. Am J Pathol 173: 1919-1928. doi:10.2353/ajpath.2008.070875. PubMed: 18988796.
25. Weidner N (1995) Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 36: 169-180. doi:10.1007/BF00666038. PubMed: 8534865.
26. Röck K, Meusch M, Fuchs N, Tigges J, Zipper P et al. (2012) Estradiol protects dermal hyaluronan/versican matrix during photoaging by release of epidermal growth factor from keratinocytes. J Biol Chem 287: 20056-20069. doi:10.1074/jbc.M112.353151. PubMed: 22493503.
27. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159. doi:10.1006/abio.1987.9999. PubMed: 2440339.
28. Dai G, Freudenberger T, Zipper P, Melchior A, Grether-Beck S et al. (2007) Chronic ultraviolet B irradiation causes loss of hyaluronic acid from mouse dermis because of down-regulation of hyaluronic acid synthases. Am J Pathol 171: 1451-1461. doi:10.2353/ajpath.2007.070136. PubMed: 17982124.
29. Kinsella MG, Wight TN (1988) Isolation and characterization of dermatan sulfate proteoglycans synthesized by cultured bovine aortic endothelial cells. J Biol Chem 263: 19222-19231. PubMed: 3198623.
30. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2: 471-478. PubMed: 12748309.
31. Kharaziha P, De Raeve H, Fristedt C, Li Q, Gruber A et al. (2012) Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model. Cancer Res 72: 5348-5362. doi:10.1158/0008-5472.CAN-12-0658. PubMed: 22952216.
32. Rose A, Grandoch M, vom Dorp F, Rübben H, Rosenkranz A et al. (2010) Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells. Br J Pharmacol 160: 1690-1698. doi: 10.1111/j.1476-5381.2010. 00838.x. PubMed: 20649572.
33. Kramer MW, Golshani R, Merseburger AS, Knapp J, Garcia A et al. (2010) HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer. Eur Urol 57: 86-93. doi:10.1016/j.eururo.2009.03.057. PubMed: 19345473.
34. Szarvas T, Becker M, vom Dorp F, Gethmann C, Tötsch M et al. (2010) Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer. Cancer Sci 101: 1300-1308. doi: 10.1111/j.1349-7006. 2010.01506.x. PubMed: 20180812.
35. Tepeli E, Caner V, Büyükpinarbaşili N, Çetin GO, Düzcan F et al. (2012) Expression of ERCC1 and its clinicopathological correlations in non-small cell lung cancer. Mol Biol Rep 39: 335-341. doi:10.1007/s11033-011-0743-0. PubMed: 21553054.
36. Edwards IJ (2012) Proteoglycans in prostate cancer. Nat. Rev Urol 9: 196-206. doi:10.1038/nrurol.2012.19.
37. Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S et al. (2009) Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457: 102-106. doi:10.1038/nature07623. PubMed: 19122641.
38. Mantovani A (2009) Cancer: Inflaming metastasis. Nature 457: 36-37. doi:10.1038/457036a. PubMed: 19122629.
39. Berendsen AD, Fisher LW, Kilts TM, Owens RT, Robey PG et al. (2011) Modulation of canonical Wnt signaling by the extracellular matrix component biglycan. Proc Natl Acad Sci U S A 108: 17022-17027. doi: 10.1073/pnas. 1110629108. PubMed: 21969569.
40. White BD, Chien AJ, Dawson DW (2012) Dysregulation of Wnt/beta-catenin signaling in gastrointestinal cancers. Gastroenterology 142: 219-232. doi:10.1053/j.gastro.2011.12.001. PubMed: 22155636.
41. Ahmad I, Morton JP, Singh LB, Radulescu SM, Ridgway RA et al. (2011) beta-Catenin activation synergizes with PTEN loss to cause bladder cancer formation. Oncogene 30: 178-189. doi:10.1038/onc.2010.399. PubMed: 20818428.
42. Ahmad I, Patel R, Liu Y, Singh LB, Taketo MM et al. (2011) Ras mutation cooperates with beta-catenin activation to drive bladder tumourigenesis. Cell Death. Drosophila Inf Serv 2: e124.
43. Nastase MV, Young MF, Schaefer L (2012) Biglycan: a multivalent proteoglycan providing structure and signals. J Histochem Cytochem 60: 963-975. doi:10.1369/0022155412456380. PubMed: 22821552.
44. Tzai TS, Lin CI, Shiau AL, Wu CL (1998) Antisense oligonucleotide specific for transforming growth factor-beta 1 inhibit both in vitro and in vivo growth of MBT-2 murine bladder cancer. Anticancer Res 18: 1585-1589. PubMed: 9673374.
45. Shabbir M, Burnstock G (2009) Purinergic receptor-mediated effects of adenosine 5'-triphosphate in urological malignant diseases. Int J Urol 16: 143-150. doi:10.1111/j.1442-2042.2008.02207.x. PubMed: 19183233.
46. Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J et al. (2012) Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 1: 894-907. doi:10.4161/onci.20931. PubMed: 23162757.
47. Singh V, Srivastava N, Kapoor R, Mittal RD (2012) Single-nucleotide Polymorphisms in Genes Encoding Toll-like Receptor -2, -3, -4, and -9 in a Case-Control Study with Bladder Cancer Susceptibility in a North Indian Population. Arch Med Res.
48. Ayari C, Bergeron A, LaRue H, Ménard C, Fradet Y (2011) Toll-like receptors in normal and malignant human bladders. J Urol 185: 1915-1921. doi:10.1016/j.juro.2010.12.097. PubMed: 21421234.
49. Metalli D, Lovat F, Tripodi F, Genua M, Xu SQ et al. (2010) The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinasedependent activation of paxillin. Am J Pathol 176: 2997-3006. doi: 10.2353/ajpath.2010. 090904. PubMed: 20395438.
50. Iozzo RV, Buraschi S, Genua M, Xu SQ, Solomides CC et al. (2011) Decorin antagonizes IGF receptor I (IGF-IR) function by interfering with IGF-IR activity and attenuating downstream signaling. J Biol Chem 286: 34712-34721. doi:10.1074/jbc.M111.262766. PubMed: 21840990.
51. Dreicer R, Li H, Stein M, DiPaola R, Eleff M et al. (2009) Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer 115: 4090-4095. doi: 10.1002/cncr.24467. PubMed: 19536901.
52. Sridhar SS, Winquist E, Eisen A, Hotte SJ, McWhirter E et al. (2011) A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Invest New Drugs 29: 1045-1049. doi:10.1007/s10637-010-9408-4. PubMed: 20191303.
53. Niedworok C, Kretschmer I, Röck K, vom Dorp F, Szarvas T et al. (2013) The impact of the receptor of hyaluronan-mediated motility (RHAMM) on human urothelial transitional cell cancer of the bladder. PLOS ONE 8: e75681. doi:10.1371/journal.pone.0075681. PubMed: 24069434.